INmune Bio To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1

5/30/24 8:18:29 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $INMB alert in real time by email

INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

Get the next $INMB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INMB

Date	Price Target	Rating	Analyst
10/21/2024	$20.00	Buy	Alliance Global Partners
9/27/2024	$18.00	Outperform	Raymond James
8/22/2024	$22.00	Sector Outperform	Scotiabank
6/1/2023	$16.00	Outperform	Robert W. Baird
5/24/2022	$14.00 → $7.00	Buy → Neutral	B. Riley Securities
1/24/2022	$32.00 → $20.00	Buy	B. Riley Securities
7/7/2021	$32.00 → $42.00	Buy	Maxim Group

More analyst ratings

$INMB
Financials

Live finance-specific insights

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.
10/31/24 4:05:51 PM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the IN
10/24/24 9:30:00 AM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2024 and provides a business update. Q2 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The Phase 2 randomized, blinded clinical trial for patients with Early Alzheimer's Disease is on schedule to reach its final enrollment before the end of Q3 followed by top-line data approximately six months fr
8/1/24 4:05:39 PM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$INMB
Press Releases

Fastest customizable press release news feed in the world

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease announced today that it completed randomization of patients for its Phase 2 trial on Monday, November 11th. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation. "We are excited to have completed administering first doses to all patients enrolled in our phase 2 Alzheimer's trial," stated RJ Tesi PhD, the CEO of INmune Bio. "A global trial of thi
11/13/24 9:00:00 AM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer's Disease ("AD") trial on Friday, 27 September. This global, blinded, randomized Phase 2 trial (the "AD02 trial") is focused on patients with Early AD and biomarkers of elevated neuroinflammation.
10/31/24 4:05:51 PM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
"Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials" Webinar to be Held on November 7, 2024, at 1 PM ET. Poster on EMACC Sensitivity and Performance in Phase II Alzheimer's Trial to be Presented at CTAD2024 Boca Raton, Florida, Oct. 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is hosting a Webinar on November 7, 2024 at 1 PM ET. The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials," will explore the
10/28/24 8:00:00 AM ET
$INMB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

INmune Bio To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1

Chat with this insight

Recent Analyst Ratings for $INMB

$INMB Insider purchases explained

Analytical look into recent insider purchases

Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

$INMB Financials

Live finance-specific insights

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

$INMB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alliance Global Partners initiated coverage on INmune Bio with a new price target

Raymond James initiated coverage on INmune Bio with a new price target

Scotiabank initiated coverage on INmune Bio with a new price target

$INMB Press Releases

Fastest customizable press release news feed in the world

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

$INMB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

$INMB Market Insights

Live Market Insights

INmune Highlights Publication Titled 'Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy'

INmune Bio Completes Blinded Interim Analysis Of Its Phase II Alzheimer's Disease Trial, Says 'The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.'

Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

$INMB SEC Filings

$INMB Leadership Updates

Live Leadership Updates

$INMB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

INmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

INmune Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

INmune Bio Inc. to Join Russell 3000® Index

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

$INMB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by INmune Bio Inc.

Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

SEC Form SC 13G filed by INmune Bio Inc.

Recent Analyst Ratings for
$INMB

$INMB
Insider purchases explained

$INMB
Financials

$INMB
Analyst Ratings

$INMB
Press Releases

$INMB
Insider Purchases

$INMB
Market Insights

$INMB
SEC Filings

$INMB
Leadership Updates

$INMB
Insider Trading

$INMB
Large Ownership Changes